0
Your cart

Your cart is empty

Books > Medicine > Clinical & internal medicine > Haematology

Buy Now

Myeloma Bone Disease (Paperback, 2010 ed.) Loot Price: R5,814
Discovery Miles 58 140
Myeloma Bone Disease (Paperback, 2010 ed.): G. David Roodman

Myeloma Bone Disease (Paperback, 2010 ed.)

G. David Roodman

Series: Current Clinical Oncology

 (sign in to rate)
Loot Price R5,814 Discovery Miles 58 140 | Repayment Terms: R545 pm x 12*

Bookmark and Share

Expected to ship within 10 - 15 working days

Multiple myeloma is the second most common hematologic malignancy and c- rently affects approximately 50,000 people in the United States. Each year about 20,000 people are diagnosed with myeloma. Although new treatments have been developed, which signi?cantly prolong the survival of patients, myeloma bone d- ease still remains a major cause of severe morbidity and increased mortality in patients with myeloma. Myeloma bone disease is characterized by "punched out" lytic lesions caused by increased osteoclastic bone destruction accompanied by suppressed or even absent osteoblast activity. Advances in our understanding of both the pathophysiology of myeloma bone disease and the development of novel agents that target speci?c pathways involved in both the increased osteoclast f- mation and the suppressed osteoblast activity in myeloma provide new hope for these patients. The treatment of myeloma bone disease was revolutionized by cl- ical trials that demonstrated the signi?cant bene?t of intravenous bisphosphonate therapy in patients with myeloma bone disease. With the identi?cation of many of the cytokines and chemokines involved in myeloma bone disease, novel th- apies such as denosumab that blocks RANKL activity, anti-DKK1, which targets the inhibition of osteoblast activity by blocking Wnt signaling inhibition, and the potential anabolic effects of agents such as bortezomib and activin have greatly improved our potential to block the progression or reverse myeloma bone disease.

General

Imprint: HumanaPress
Country of origin: United States
Series: Current Clinical Oncology
Release date: July 2012
First published: 2010
Editors: G. David Roodman
Dimensions: 235 x 155 x 14mm (L x W x T)
Format: Paperback
Pages: 252
Edition: 2010 ed.
ISBN-13: 978-1-61779-688-3
Categories: Books > Medicine > Clinical & internal medicine > Haematology
Books > Medicine > Clinical & internal medicine > Diseases & disorders > Oncology > Radiotherapy
Promotions
LSN: 1-61779-688-3
Barcode: 9781617796883

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!

You might also like..

Neuroendocrine Tumors, An Issue of…
Jennifer Chan, Matthew Kulke Hardcover R1,696 Discovery Miles 16 960
Blood Banking and Transfusion Medicine…
Christopher D. Hillyer, Leslie E. Silberstein, … Hardcover R4,389 Discovery Miles 43 890
Clinical Pathology of the Blood; A…
James Ewing Paperback R676 Discovery Miles 6 760
Anticoagulation - Current Perspectives
Xingshun Qi, Xiaozhong Guo Hardcover R3,081 Discovery Miles 30 810
Nanotechnology for Hematology, Blood…
Adil Denizli, Tuan Anh Nguyen, … Paperback R4,540 Discovery Miles 45 400
Cheto - When live gives you lemons, make…
Tim Foster Hardcover R609 Discovery Miles 6 090
Beta Thalassemia
Marwa Zakaria, Tamer Hassan Hardcover R3,076 Discovery Miles 30 760
Advanced Hematology in Integrated…
Anika Niambi Al-Shura Paperback R3,224 Discovery Miles 32 240
Highlights on Hemodynamics
Theodoros Aslanidis Hardcover R2,553 Discovery Miles 25 530
Antiphospholipid Syndrome - Recent…
Polona Zigon Hardcover R3,083 Discovery Miles 30 830
The HDL Handbook - Biological Functions…
Tsugikazu Komoda Hardcover R3,238 R3,031 Discovery Miles 30 310
Inherited Hemoglobin Disorders
Anjana Munshi Hardcover R3,098 Discovery Miles 30 980

See more

Partners